Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and innovative pipeline.” OVERALL FINANCIAL RESULTS
expand
expand
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items Note: values may have been roundedREGIONAL SALES RESULTS
expand
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Certain international OTC products, primarily in China, wer...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news
More News: Abiraterone Acetate | Arthritis | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer Vaccines | Cardiology | China Health | Conferences | Covid Vaccine | COVID-19 | Environmental Health | European Medicines Agency (EMA) | Genetics | Government | Health Management | Heart | Ibuprofen | Immunotherapy | Imodium | Invega | Invega Sustenna | Legislation | Loperamide | Lymphoma | Marketing | Medical Devices | Myeloma | Oral Cancer | Orthopaedics | Outbreaks | Pandemics | Pharmaceuticals | Podcasts | Prednisone | Profits and Losses | Prostate Cancer | Psoriasis | Psoriatic Arthritis | Radiography | Remicade | Respiratory Medicine | Rheumatology | SARS | Schizophrenia | Science | Skin | Stelara | Strategic Planning | Study | Surgery | Ukraine Health | Vaccines | Websites